Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 18/20 | 0.69 |
| ▸ | TNF | P01375 | 3/20 | 0.64 |
| ▸ | IL1B | P01584 | 3/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.64 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.64 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249657 | 0.90 | CRBN (0.76) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL24880449 | 0.85 | CRBN (0.77) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2255399 | 0.84 | CRBN (0.65) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2255396 | 0.84 | CRBN (0.65) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL30493932 | 0.84 | CRBN (0.65) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2253947 | 0.84 | CRBN (0.64) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2250308 | 0.84 | CRBN (0.64) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL29790723 | 0.84 | CRBN (0.64) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2255945 | 0.84 | CRBN (0.74) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL16768411 | 0.83 | CRBN (0.65) | CRBNIKZF3TNFIL1BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023280237-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | 海创药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |